Galmed Pharmaceuticals Ltd. EOCN

3.63 0.01 0.28% as of 25 Sep
Market cap
$3.8M
P/E
0.0×
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
— — — —

+8 more quarters

EV/Sales
— — — —
EV/FCF
— — — —
Quick Ratio
3.29 3.97 4.04 4.92
Current Ratio
4.16 7.71 6.55 7.98
Net Debt/EBITDA
3.20 3.84 3.65 5.56
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.00 0.00 0.00 0.00
Operating CF/Net income
0.78 1.33 0.40 1.02
Capex/Depreciation
0.00 0.00 0.00 0.00
Interest Coverage
0.00 0.00 0.00 0.00
Research and Development Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.35 0.00 0.00 0.00
Share Based Compensation of Revenue
0.00% 0.00% 0.00% 0.00%
Free Cash Flow Yield
— — — —
Revenue per Share
0.00 0.00 0.00 0.00
Operating CF per Share
(2.23) (3.08) (3.61) (2.84)
Capex per Share
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(2.23) (3.08) (3.61) (2.84)
Cash per Share
9.37 9.47 20.66 17.02
Shareholders Equity per Share
13.38 16.93 29.29 28.00
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
13.38 16.93 29.29 28.00
Free Cash Flow
(2.13) (2.54) (1.94) (1.93)
Working Capital
8.90 13.95 15.78 17.25
Net Current Asset Value
6.17 13.95 15.78 17.25
EV/EBIT
— — — —
Net Profit Margin
0.00% 0.00% 0.00% 0.00%
Other line items
Average Receivables
0.38 0.45 0.51 0.49
Average Payables
1.63 1.52 1.66 1.51
Average Assets
20.61 17.36 18.56 21.27
Average Common Equity
16.63 15.41 16.05 18.77

Fold the line items

Columns are period end dates